Finally, similarly for patients with partial lipodystrophy that can be treated with leptin-replacement therapy [54,55], and patients with growth hormone deficiency that show a reduction in subcutaneous and visceral fat mass after growth hormone replacement therapy [56], knowing the genes and pathways dysregulated in patients with lipedema is fundamental to find targets for pharmacological and other treatments. This evidence concerns the gene LEP and partial lipodystrophy.